Bridgebio Pharma Presents Updated Six Month Results From Phase 2 Cohort 5 Trial Of Infigratinib In Achondroplasia; Infigratinib Resulted In A Significant And Robust Increase In Annual Height Velocity, With A Mean Change Of +3.38 Cm/Year From Baseline
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma has presented updated six-month results from its Phase 2 Cohort 5 trial of Infigratinib in Achondroplasia. The drug showed a significant and robust increase in annual height velocity, with a mean change of +3.38 cm/year from baseline.

June 20, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BridgeBio Pharma's Infigratinib showed promising results in Phase 2 trial for Achondroplasia, potentially boosting the company's stock.
The positive results from the Phase 2 trial of Infigratinib in Achondroplasia indicate that the drug has potential for further development and eventual commercialization. This could lead to increased revenues for BridgeBio Pharma and a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100